Solid Power, Inc.: Q1 FY2026 earnings call
What management said about Q1 FY2026, from the documents filed with the SEC on 5 May 2026: press release. The quarter’s numbers.
Key takeaways
- Revenue and grant income declined: Total revenue and grant income was $3.073 million, against $6.016 million a year earlier. Revenue was $2.105 million, down from $5.125 million; grant income was $968 thousand, up from $891 thousand. Source
- Operating and net loss widened: Operating loss was $26.346 million, compared with $24.029 million a year earlier. Net loss was $13.028 million, or $(0.06) per share, against $15.151 million, or $(0.08) per share. Source
- SK On line acceptance testing completed: Site acceptance testing was completed for the SK On pilot cell line. Management described it as the final milestone under the line installation agreement. Source
- Operating expenses slightly lower: Operating expenses were $29.4 million, against $30.0 million a year earlier. Management attributed the reduction to the timing of supplier and material shipments. Source
- Total liquidity rose to $435.3 million: Total liquidity was $435.3 million at March 31, 2026, against $336.5 million at December 31, 2025. It comprised $31.5 million of cash and $403.8 million of available-for-sale securities. Source
- $130 million offering completed: A $130 million registered direct offering was completed in the quarter, with net proceeds of $121.3 million after fees and expenses. Source
- Pilot line moved into construction: Facilities construction began on the continuous manufacturing pilot line for sulfide electrolyte production, and factory acceptance testing of its key equipment was completed. Source
“Completion of site acceptance testing marks an important moment in our partnership with SK On and the final milestone under the line installation agreement,”
John Van Scoter, President and Chief Executive Officer
What changed from last quarter
- New: The pilot line moved from design to facilities construction, and factory acceptance testing of its key equipment was completed. The prior release described only detailed design. Source
- New: Quarter funding came from a registered direct offering. The prior release described the 2025 at-the-market program as the funding source. Source
Results and revenue
- Revenue and grant income declined: Total revenue and grant income was $3.073 million, against $6.016 million a year earlier. Revenue was $2.105 million, down from $5.125 million; grant income was $968 thousand, up from $891 thousand. Source
- Revenue tied to SK On milestone: Management said the revenue was primarily from progress toward the site acceptance testing milestone under the SK On line installation agreement. Grant income came from a U.S. Department of Energy assistance agreement. Source
- Operating and net loss widened: Operating loss was $26.346 million, compared with $24.029 million a year earlier. Net loss was $13.028 million, or $(0.06) per share, against $15.151 million, or $(0.08) per share. Source
Partner programs and sampling
- SK On line acceptance testing completed: Site acceptance testing was completed for the SK On pilot cell line. Management described it as the final milestone under the line installation agreement. Source
- Electrolyte provided to Samsung SDI: Electrolyte was supplied to Samsung SDI under the Joint Evaluation Agreement with Samsung SDI and BMW. Sampling to other customers continued. Source
- Cell lines on three continents: Management said cell production lines using the company's technology are now in Colorado, Germany and the Republic of Korea, at its own facilities and its partners' facilities. Source
“We are encouraged by our progress in the first quarter of 2026 and remain focused on supporting our customers this year.”
John Van Scoter, President and Chief Executive Officer
Operating costs and loss
- Operating expenses slightly lower: Operating expenses were $29.4 million, against $30.0 million a year earlier. Management attributed the reduction to the timing of supplier and material shipments. Source
- Direct costs up, R&D down: Direct costs were $3.548 million, up from $2.696 million. Research and development was $17.749 million, down from $19.022 million, and SG&A was $8.122 million, down from $8.327 million. Source
Balance sheet and liquidity
- Total liquidity rose to $435.3 million: Total liquidity was $435.3 million at March 31, 2026, against $336.5 million at December 31, 2025. It comprised $31.5 million of cash and $403.8 million of available-for-sale securities. Source
- Receivables and current liabilities detail: At March 31, 2026, contract assets and accounts receivable were $12.7 million, and total current liabilities were $17.1 million. Source
- Long-term investments more than doubled: Long-term investments were $181.0 million at March 31, 2026, up from $87.0 million at December 31, 2025. Source
Capital raise and cash use
- $130 million offering completed: A $130 million registered direct offering was completed in the quarter, with net proceeds of $121.3 million after fees and expenses. Source
- Operating cash use and capex: Net cash used in operating activities was $18.8 million, against $26.3 million a year earlier. Capital expenditures were $1.7 million, primarily for the continuous electrolyte pilot line. Source
Pilot line and strategy
- Pilot line moved into construction: Facilities construction began on the continuous manufacturing pilot line for sulfide electrolyte production, and factory acceptance testing of its key equipment was completed. Source
- Korean partner search continues: The company continued to explore potential partners for commercial-scale electrolyte production in the Republic of Korea. Source
- Business model: sell electrolyte, license designs: The company describes its core technology as its electrolyte material. Its model is selling electrolyte to cell manufacturers and licensing its cell designs and manufacturing processes. Source
Non-operating items and shares
- Warrant liability gain: The change in fair value of warrant liabilities was a $9.6 million gain, against $5.9 million a year earlier. Warrant liabilities were $4.2 million at March 31, 2026, down from $13.9 million. Source
- Interest income rose: Interest income was $4.0 million, compared with $3.6 million in the first quarter of 2025. Source
- Shares outstanding increased: Shares issued and outstanding rose to 224,519,421 at March 31, 2026, from 201,181,175 at December 31, 2025. Source
Coming up, as management said on 5 May 2026
- Pilot line commissioning by year end: Management said commissioning of the continuous pilot line is on track for the end of 2026. Source
Earlier plans management reported on
- Met: Site acceptance testing for the SK On pilot cell line was completed, which management described as the final milestone under the line installation agreement. Source
Other quarters
Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.